Stada Prepares for Potential Multi-Billion Euro IPO

The German pharmaceutical company could be valued at up to €12 billion, with investor interest spanning multiple regions.

Stada is planning a potential IPO in Frankfurt before Easter, aiming for a valuation between €10 and €12 billion.
The company, known for products like Grippostad and Ladival, has seen significant growth, with 2024 revenue rising 9% to over €4 billion.
Stada's private equity owners, Bain Capital and Cinven, are expected to retain stakes post-IPO, though the number of shares to be sold remains unclear.
The IPO could reduce Stada's debt, enabling future acquisitions and strengthening its specialty medicines division.
The final decision on the IPO will depend on market conditions, with geopolitical risks cited as a key consideration.